OncoZenge AB (OSTO:ONCOZ) ROCE % : -54.36% (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is OncoZenge AB ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. OncoZenge AB's annualized ROCE % for the quarter that ended in Mar. 2024 was -54.36%.

OncoZenge AB ROCE % Historical Data

The historical data trend for OncoZenge AB's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OncoZenge AB ROCE % Chart

OncoZenge AB Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

ROCE %

-2.74

-8.93

-35.70

-60.45

OncoZenge AB Quarterly Data
	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial									-50.75	-64.93	-72.23	-64.06	-54.36

OncoZenge AB ROCE % Calculation

OncoZenge AB's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-15.902	/	( ( (36.893 - 2.92)	+	(20.34 - 1.699) )	/ 2 )
	=	-15.902	/	( (33.973	+	18.641)	/ 2 )
	=	-15.902	/	26.307
	=	-60.45 %

OncoZenge AB's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	-9.488	/	( ( (20.34 - 1.699)	+	(17.233 - 0.967) )	/ 2 )
	=	-9.488	/	( ( 18.641	+	16.266 )	/ 2 )
	=	-9.488	/	17.4535
	=	-54.36 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

OncoZenge AB (OSTO:ONCOZ) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

OncoZenge AB ROCE % Related Terms

Thank you for viewing the detailed overview of OncoZenge AB's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

OncoZenge AB (OSTO:ONCOZ) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OncoZenge AB (OSTO:ONCOZ) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

8LY:Germany

Address

Gustavslundsvagen 34, Bromma, SWE, 167 51

Website

https://www.oncozenge.com

OncoZenge AB is a pharmaceutical company that is developing a new treatment for effective pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer. In phase 2 patient studies, the company's product candidate BupiZenge displayed pain relief compared with standard therapy. It focuses on implementing a phase development program as a basis for regulatory approvals and product launches.

OncoZenge AB (OSTO:ONCOZ) Headlines

No Headlines